Preliminary data indicate tolerability and disease control with bexmarilimab in hard-to-treat solid tumours

A significant progression-free survival improvement after re-treatment with olaparib was reported in the OReO/ENGOT Ov-38 trial

Research and treatment approaches have come a long way since triple-negative breast cancer was first recognised, but there is still progress to be made, according to Associate Prof. Rebecca Dent 

We were hoping to be in Paris for the ESMO Congress 2021, but the event will be virtual for the second consecutive year due to the COVID-19 pandemic. However, this annual Congress will confirm that cancer research is blooming again, despite the current health crisis and its remarkable consequences on people, healthcare system, and, not the least, research

Long-term outcomes of the phase III study confirm that only the addition of carboplatin to paclitaxel impacts on pathological complete response and event-free survival

Reduced access to insurance, bank loans and mortgages makes financial constraints continue long after cancer has been treated 

OnCOVID study reveals that respiratory symptoms, fatigue and cognitive/psychological dysfunction persist after acute Sars-CoV-2 infection, with an impact on survival and oncological outcomes after recovery 

Presented at the ESMO Virtual Plenaries this year, four key studies in oncology will animate the debate  

Nearly 1 in 4 patients with pleural malignancy continue to benefit from nivolumab plus ipilimumab at 3 years 

International oncology experts reunited as one oncology community to share the latest advances in the field at the ESMO annual meeting starting next week